# US 12,600,778 B2 · Rage antibodies, fragments and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,600,778 B2
- Document ID: US12600778B2
- Status: Granted
- Kind: B2
- Application number: 17/772,853
- Filed: 2020-11-02
- Published: 2022-12-15
- Granted: 2026-04-14
- Earliest claimed: 2019-10-31
- Assignees: The Research Foundation for The State University of New York; The Regents of the University of California
- Applicants: The Research Foundation for The State University of New York; The Regents of the University of California
- Inventors: Ding Xu; Jeffrey Esko; Miaomiao Li
- Web page: https://patentgrep.com/patent/US12600778B2

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 19/10: for osteoporosis
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are antibodies specific for the heparan sulfate binding site of Receptor for Advanced Glycation Endproducts (RAGE). Also provided are methods for treating of conditions in which RAGE is involved comprising administration of the antibodies to an individual in need of treatment.

## Claims

### Claim 1

An isolated antibody that binds to heparin sulfate binding site of Receptor for Advanced Glycation Endproducts (RAGE) on a cell and does not interfere with the binding of RAGE ligands to RAGE on the cell, said antibody comprising a variable light chain (VL) and a variable heavy chain (VH), and wherein CDRL1 comprises the sequence denoted in SEQ ID NO: 1, the CDRL2 comprises the sequence demoted by SEQ ID NO: 2, the CDRL3 comprises the sequence denoted by SEQ ID NO: 3, the CDRH1 comprises the sequence denoted by SEQ ID NO: 4, the CDRH2 comprises the sequence denoted by SEQ ID NO: 5, and the CDRH3 comprises the sequence denoted by SEQ ID NO: 6.

### Claim 2 (depends on 1)

The isolated antibody of claim 1, wherein the antibody is a chimeric antibody, a humanized antibody, a single chain antibody, a bispecific antibody or a multispecific antibody.

### Claim 3 (depends on 1)

The isolated antibody of claim 1, wherein the antibody has an isotype of IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgD or IgE.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising an isolated antibody of claim 1 and a pharmaceutically acceptable carrier.